Camurus’ treatment Buvidal® subsidised in Australia
Australia has announced that Camurus’ treatment Buvidal® (buprenorphine) will be listed through the Pharmaceutical Benefit Scheme (PBS).
From September 1, Buvidal® will be fully subsidised for treatment of opioid depence in Australia. In total, over 110 000 australians are struggling with opioid dependence, and approximately 50 000 people are treated daily. Australian Federal Health Ministrer Greg Hunt has announced that Buvidal® provides a more flexible option than current daily monitored treatments.